Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Every row

Showing 6 of 382 rows for Psychotropics for agitation / psychosis. One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 6 rows. Every row links to its source.
Exposure Question Direction Outcome measured Design People Effect size, as the source reported it Source
Psychotropics for agitation / psychosis Medicines Treatment Benefit
why

The NPI-C agitation/aggression measure did not reach significance (p=0.094).

Pittsburgh Agitation Scale over 3 weeks phase 2 trial 75 PAS decline difference -0.74/week (p=0.015, ES 0.53); NPI-C A/A -1.26/week (p=0.094, ES 0.36) The American Journal of Geriatric Psychiatry 2026
✓ Peer-reviewed PMID 41350162
Psychotropics for agitation / psychosis Medicines Treatment No effect
why

Not effective, and drug-related QT prolongation was observed. The randomised sample was smaller than planned.

Clinically significant improvement in agitation at 12 weeks phase 3 trial 173 Risk difference for clinically significant improvement 0.08 (95% CI -0.21 to 0.06) Nature Medicine 2025
✓ Peer-reviewed PMID 40133524
Psychotropics for agitation / psychosis Medicines Treatment No direction reported
why

A feasibility trial in 29 residents: designed to test whether the trial can be run, not powered for efficacy, and it reports no efficacy estimate.

Feasibility, adherence and safety randomised trial 29 100% adherence; no withdrawals; 0 adverse reactions Age and Ageing 2025
✓ Peer-reviewed PMID 40479610
Psychotropics for agitation / psychosis Medicines Treatment Benefit
why

The authors describe the reduction as small (-1.32 points).

NPI apathy score at 6 weeks phase 2 trial 94 NPI apathy change -1.32 points (95% CI -2.43 to -0.21) vs placebo The Lancet Neurology 2025
✓ Peer-reviewed PMID 39862881
Psychotropics for agitation / psychosis Medicines Treatment Benefit
why

A post hoc dementia subgroup of a randomised-withdrawal trial that was not designed or powered for it; 46 randomised responders. The authors say to read it cautiously.

Psychosis relapse over up to 26 weeks phase 3 trial 76 Psychosis relapse HR 0.031 (95% CI 0.010-0.103) vs placebo among 46 randomised responders BMC Neurology 2025
✓ Peer-reviewed PMID 41286676
Psychotropics for agitation / psychosis Medicines Treatment Benefit
why

Both doses beat placebo. Treatment-emergent adverse events were more common than placebo (84.6% at 2 mg, 76.8% at 1 mg, 73.8% placebo).

Cohen-Mansfield Agitation Inventory at week 10 phase 3 trial not stated CMAI change vs placebo: -7.2 (95% CI -10.0 to -4.3) at 2 mg; -3.7 (95% CI -6.8 to -0.7) at 1 mg Alzheimer's & Dementia 2024
✓ Peer-reviewed PMID 39369280

How this table was built, and where it is weak →

Last updated